# A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis

> **NCT06474442** · PHASE2 · RECRUITING · sponsor: **Shanghai BDgene Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Herpes Simplex Virus Type I Stromal Keratitis

## Interventions

- **GENETIC:** BD111 Injection (investigational new drug)
- **COMBINATION_PRODUCT:** Triple-drugs therapy of HSV-1 stromal keratitis

## Key facts

- **NCT ID:** NCT06474442
- **Lead sponsor:** Shanghai BDgene Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-28
- **Primary completion:** 2026-12
- **Final completion:** 2027-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06474442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06474442, "A Phase Ⅱa Study of the Safety, Tolerability and Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06474442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*